Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss

Tranexamic Acid Versus Calcium Dobesilate for the Treatment of Copper Intra Uterine Contraceptive Device Associated Heavy Menstrual Blood Loss : A Randomized , Open-labelled , Clinical Trial.

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03139422

Enrollment

140

Registered

2017-05-04

Start date

2017-07-01

Completion date

2018-12-31

Last updated

2018-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menorrhagia

Brief summary

Intrauterine contraceptive device is the most commonly reversible method used among women of reproductive age worldwide. Almost one in five married contraceptive users is currently using Intrauterine contraceptive device. The Egyptian demographic and health survey results indicate that 30% of currently married women interviewed in the Egyptian demographic and health survey were using Intrauterine contraceptive device. Main reasons for discontinuation of Intrauterine contraceptive device as cited by women were excessive bleeding per vagina 39.68%, abdominal pain 38.62%, low backache35.97%.

Interventions

DRUGCalcium Dobesilate

oral tablets

DRUGTranexamic Acid 500 MG

oral tablets

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

1. Women usingsopperT380A and reporting heavy menstrual blood loss during use. 2. Menorrhagia , will be defined as a Pictorial blood loss assessment chart-Score greater than 100. 3. No contraindication to drugs used in treatment. 4. No other cause for heavy menstrual blood loss

Exclusion criteria

1. Refusing to participate. 2. Irregular menstrual cycle. 3. Misplaced Intrauterine device.

Design outcomes

Primary

Measure	Time frame
Percent of women requesting treatment for heavy menstrual blood loss.	3 months

Countries

Egypt

Contacts

Primary ContactEriny Morris, MBBCh

ranamorris76@yahoo.com00201203211136

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026